Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analyses of Atlantic salmon muscle genes induced by DNA vaccine against salmon alphavirus subtype 3 (SAV3)

ABSTRACT: Vaccination of pre-smolt salmon with a plasmid encoding the structural polypeptide of salmonid alphavirus subtype 3 (SAV3) gives protection against infection and development of pancreas disease (PD) mediated with production of antibodies against the virus. The present study analysed transcript responses in the muscle to vaccination with this plasmid (pSAV), pcDNA3.3 was used as a control. pSAV and pcDNA3.3 had similar abilities to up-regulate typical type I IFN stimulated genes. In contrast, pSAV caused higher up-regulation of IFNγ and several IFNγ inducible genes. Compared to pcDNA3.3, pSAV also gave larger increase in transcripts of marker genes for B-cells, T-cells and antigen presenting cells (APCs), which suggests attraction of these cells and that their role in the adaptive immune response elicited by pSAV.

ORGANISM(S): Salmo salar Oncorhynchus mykiss

PROVIDER: GSE115689 | GEO | 2018/06/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Responses of Atlantic salmon to vaccination and challenge with salmon alphavirus (SAV) and Moritella viscosa

Project description:Salmon alphavirus (SAV) and Moritella viscosa causing respectively pancreatic disease and winter ulcer are among the most important pathogens threatening Atlantic salmon aquaculture. Fish is protected by vaccination with different rate of success. Here, responses to vaccination were assessed followed with pathogen challenges of vaccinated salmon and saline injected control.

2021-04-23 | GSE173130 | GEO

Transcription profiling by array of Atlantic salmon infected with salmoin alphavirus

Project description:Salmon pancreas disease, caused by salmonid alphavirus (SAV), is an economically important disease affecting farmed Atlantic salmon (Salmo salar L.) in Europe, with outbreaks reported in Scotland, Norway, and Ireland. A microarray-based study was performed to evaluate the host transcriptomic response during the early stages of an experimentally induced salmonid alphavirus 1 (SAV 1) infection in Atlantic salmon (Salmo salar L.) Head kidney was sampled from five fish PD infected Atlantic salmon parr and uninfected controls on days 1, 3 and 5 post injection (d.p.i). RNA from tissue samples was amplified and interrogated using the 17k TRAITS / SGP cDNA microarray, with results validated by SYBR green real-time PCR. The greatest number of significantly differentially expressed genes was recorded on day 3 p.i. These were found to be mainly associated with immune and defence mechanisms including genes involved in interferon I & II pathways and major histocompatibility complex class I & II responses. The expression of genes associated with apoptosis (BcL2 and caspase 3/7) and cellular stress (heat shock protein) were also found to differ significantly between infected and uninfected individuals as were genes involved in inhibiting viral attachment and replication, such as ubiquitin, serum myeloid, and and viperin.

2011-06-01 | E-TABM-1060 | biostudies-arrayexpress

Responses of Atlantic salmon to vaccination and challenge with salmon alphavirus (SAV) and Moritella viscosa

Project description:Responses of Atlantic salmon to vaccination and challenge with salmon alphavirus (SAV) and Moritella viscosa

| PRJNA723861 | ENA

De Novo assembly and transcriptome analysis of Atlantic salmon macrophage/dendritic-like TO cells following type I IFN treatment and Salmonid alphavirus subtype-3 infection

Project description:We used RNA-seq to characterize the transcriptomic changes induced by type I IFN treatment and salmon alphavirus subtype 3 (SAV-3) infection in TO-cells, a macrophage/dendritic like cell-line derived from Atlantic salmon (Salmo salar L) head kidney leukocytes.

2014-12-31 | GSE64095 | GEO

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [human]

Project description:Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-APCs (TR-APCs). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology.

2022-12-31 | GSE216559 | GEO

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [mouse]

2022-12-31 | GSE216229 | GEO

Transcriptome analyses of Atlantic salmon muscle genes induced by DNA vaccine against salmon alphavirus subtype 3 (SAV3)

Project description:Transcriptome analyses of Atlantic salmon muscle genes induced by DNA vaccine against salmon alphavirus subtype 3 (SAV3)

| PRJNA475766 | ENA

Alphavirus infection triggers antiviral RNAi immunity in mammals

Project description:RNA interference (RNAi) functions as an antiviral immune response in plants and invertebrates, whereas mammalian RNAi response has been found so far only in undifferentiated cells and in differentiated cells inactive in interferon (IFN) system or in infections with viruses disabling viral suppressors of RNAi (VSRs), thereby leading to question the physiological importance of the RNAi pathway in mammals. Here, we identified that wild-type Semliki Forest virus (SFV), a prototypic alphavirus, triggered the Dicer-dependent production of abundant viral (v)siRNAs in different mammalian somatic cells in the presence of VSR. These vsiRNAs were produced from viral dsRNA replicative intermediates, almost exclusively located at the 5’ termini of the viral genome, and loaded into AGO, and they were fully active in slicing cognate viral RNAs. Besides, Sindbis virus, another alphavirus, also induced vsiRNA generation in mammalian somatic cells. AGO2 deficiency increased SFV and SINV replication, while enoxacin, a known RNAi enhancer that functions at post steps of siRNA production, efficiently reduced viral replication. The nucleotide sequence at the 5’ termini of SFV and SINV genome is conserved among the Old World alphaviruses, and mutating the conserved sequences resulted in the recombinant SFV being deficient in vsiRNA production and irresponsive to antiviral RNAi. SFV infection also enabled the production of abundant vsiRNAs and antiviral RNAi in IFN-competent adult mice, and importantly, enhanced RNAi by enoxacin protected adult mice from lethal SFV challenge and reduced the virus-induced neuropathogenesis in the central neuron system. Overall, our findings provide evidence that mammalian antiviral RNAi is active in differentiated cells and adult mice with intact IFN response even in the presence of VSR and present a therapeutic strategy against alphaviruses that include many important emerging and reemerging human pathogens.

2022-10-04 | GSE214453 | GEO

Alphavirus infection triggers antiviral RNAi immunity in mammals

Project description:Alphavirus infection triggers antiviral RNAi immunity in mammals

| PRJNA885440 | ENA

Agua-Salud alphavirus, Aedes aegypti cell lines

Project description:Antiviral RNAi response against the insect specific Agua Salud alphavirus

| PRJNA725665 | ENA